Amoxicillin
Amoxicillin, Amoxicillin /, Amoxicillin / /, Amoxil, Augmentin, Larotid, Omeclamox-pak, Talicia, Voquezna (amoxicillin) is a small molecule pharmaceutical. Amoxicillin was first approved as Amoxil on 1982-01-01. It is used to treat actinomycosis, bacterial infections, bacterial skin diseases, chlamydia infections, and duodenal ulcer amongst others in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Trade Name
FDA
EMA
Amoxicillin, Amoxil (discontinued: Amoxicillin, Amoxil, Dispermox, Larotid, Moxatag, Polymox, Trimox, Utimox, Wymox)
CombinationsAmoxicillin clavulanate potassium, Augmentin, Lansoprazole, amoxicillin clarithromycin, Talicia, Voquezna dual, Voquezna triple (discontinued: Amoxicillin clavulanate potassium, Augmentin, Lansoprazole, amoxicillin clarithromycin, Omeclamox-pak, Prevpac)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Amoxicillin
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| AMOXIL | USAntibiotics | N-050760 RX | 1999-04-15 | 1 products, RLD |
Show 8 discontinued
Amoxicillin
+
Clarithromycin
+
Lansoprazole
Amoxicillin
+
Omeprazole magnesium
+
Rifabutin
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| TALICIA | RedHill Biopharma | N-213004 RX | 2019-11-01 | 1 products, RLD, RS |
Amoxicillin
+
Clarithromycin
+
Omeprazole
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| OMECLAMOX-PAK | Cumberland Pharmaceuticals | N-050824 DISCN | 2011-02-08 | 1 products, RLD |
Hide discontinued
Amoxicillin
+
Vonoprazan fumarate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| VOQUEZNA DUAL PAK | Phathom Pharmaceuticals | N-215153 RX | 2022-05-03 | 1 products, RLD, RS |
Amoxicillin
+
Clarithromycin
+
Vonoprazan fumarate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| VOQUEZNA TRIPLE PAK | Phathom Pharmaceuticals | N-215152 RX | 2022-05-03 | 1 products, RLD, RS |
Amoxicillin
+
Clavulanate potassium
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| AUGMENTIN '125' | USAntibiotics | N-050575 RX | 1984-08-06 | 1 products, RLD |
| AUGMENTIN '250' | USAntibiotics | N-050575 RX | 1984-08-06 | 1 products, RLD, RS |
| AUGMENTIN '875' | USAntibiotics | N-050720 RX | 1996-02-13 | 1 products, RLD |
| AUGMENTIN ES-600 | USAntibiotics | N-050755 RX | 2001-06-22 | 1 products, RLD |
Show 9 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| amoclan | 2009-01-07 | |
| amoxicillin | ANDA | 2025-08-25 |
| amoxicillin 500 mg | ANDA | 2025-01-14 |
| amoxicillin amoxicillin and clavulanate potassium | ANDA | 2024-01-09 |
| amoxicillin and clavulanate potassium | NDA authorized generic | 2025-08-28 |
| amoxicillin and clavulanate potassium extended release | New Drug Application | 2011-04-07 |
| amoxicillin clav/pot amoxicillin/clav pot | ANDA | 2023-04-20 |
| amoxicillin clavulanate potassium | 2006-11-03 | |
| amoxicillin/clav pot | ANDA | 2025-08-01 |
| amoxicillin/clav pot oral susp | ANDA | 2025-01-22 |
Show 11 more
Indications
FDA
EMA
Show 20 more
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
AMOXICILLIN / CLARITHROMYCIN / VONOPRAZAN FUMARATE, VOQUEZNA TRIPLE PAK, PHATHOM | |||
| 2032-05-03 | GAIN | ||
| 2027-05-03 | NCE | ||
AMOXICILLIN / VONOPRAZAN FUMARATE, VOQUEZNA DUAL PAK, PHATHOM | |||
| 2032-05-03 | GAIN | ||
| 2027-05-03 | NCE | ||
AMOXICILLIN / OMEPRAZOLE MAGNESIUM / RIFABUTIN, TALICIA, REDHILL | |||
| 2027-11-01 | GAIN | ||
| 2022-11-01 | NP | ||
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Amoxicillin / Omeprazole Magnesium / Rifabutin, Talicia, Redhill | |||
| 11878011 | 2042-05-27 | U-3816 | |
| 9050263 | 2034-02-12 | DP | U-2660 |
| 9498445 | 2034-02-12 | DP | U-2660 |
| 9603806 | 2034-02-12 | DP | U-2660 |
| 10238606 | 2034-02-12 | DP | |
| 11135172 | 2034-02-12 | DP | U-2660 |
| Amoxicillin / Clarithromycin / Vonoprazan Fumarate, Voquezna Triple Pak, Phathom | |||
| 9186411 | 2030-08-11 | DP | |
| 7977488 | 2028-08-11 | DP | |
| Amoxicillin, Moxatag, Pragma | |||
| 8299052 | 2027-05-07 | U-1304 | |
| 8357394 | 2026-12-08 | DP | |
| 8778924 | 2026-12-08 | DS, DP | U-897 |
ATC Codes
A: Alimentary tract and metabolism drugs
— A02: Drugs for acid related disorders
— A02B: Drugs for peptic ulcer and gastro-oesophageal reflux disease (gord)
— A02BD: Combinations for eradication of helicobacter pylori
— A02BD01: Omeprazole, amoxicillin and metronidazole
— A02BD03: Lansoprazole, amoxicillin and metronidazole
— A02BD04: Pantoprazole, amoxicillin and clarithromycin
— A02BD05: Omeprazole, amoxicillin and clarithromycin
— A02BD06: Esomeprazole, amoxicillin and clarithromycin
— A02BD07: Lansoprazole, amoxicillin and clarithromycin
— A02BD10: Lansoprazole, amoxicillin and levofloxacin
— A02BD11: Pantoprazole, amoxicillin, clarithromycin and metronidazole
— A02BD12: Rabeprazole, amoxicillin and clarithromycin
— A02BD13: Rabeprazole, amoxicillin and metronidazole
— A02BD14: Vonoprazan, amoxicillin and clarithromycin
— A02BD15: Vonoprazan, amoxicillin and metronidazole
— A02BD16: Omeprazole, amoxicillin and rifabutin
J: Antiinfectives for systemic use
— J01: Antibacterials for systemic use
— J01C: Beta-lactam antibacterials, penicillins
— J01CA: Penicillins with extended spectrum
— J01CA04: Amoxicillin
— J01CR: Combinations of penicillins, incl. beta-lactamase inhibitors
— J01CR02: Amoxicillin and beta-lactamase inhibitor
HCPCS
Code | Description |
|---|---|
| G9313 | Amoxicillin, with or without clavulanate, not prescribed as first line antibiotic at the time of diagnosis for documented reason |
| G9314 | Amoxicillin, with or without clavulanate, not prescribed as first line antibiotic at the time of diagnosis, reason not given |
| G9315 | Amoxicillin, with or without clavulanate, prescribed as a first line antibiotic at the time of diagnosis |
Clinical
Clinical Trials
995 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Infections | D007239 | EFO_0000544 | — | 15 | 23 | 61 | 157 | 103 | 343 |
| Helicobacter infections | D016481 | EFO_1000961 | — | 7 | 15 | 25 | 65 | 49 | 152 |
| Communicable diseases | D003141 | — | — | 1 | 6 | 27 | 55 | 42 | 127 |
| Pneumonia | D011014 | EFO_0003106 | J18 | 4 | 8 | 20 | 22 | 18 | 66 |
| Gastritis | D005756 | EFO_0000217 | K29.7 | 3 | 3 | 13 | 35 | 9 | 61 |
| Periodontitis | D010518 | EFO_0000649 | K05.3 | 1 | 5 | 6 | 11 | 18 | 38 |
| Sinusitis | D012852 | EFO_0007486 | J32 | — | 1 | 7 | 15 | 8 | 31 |
| Dyspepsia | D004415 | EFO_0008533 | K30 | 1 | 3 | 3 | 16 | 5 | 28 |
| Healthy volunteers/patients | — | — | — | 14 | 1 | 1 | 3 | 7 | 26 |
| Hypersensitivity | D006967 | EFO_0003785 | T78.40 | 2 | 1 | 1 | 4 | 11 | 19 |
Show 183 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Lymphoma | D008223 | — | C85.9 | — | 3 | 2 | — | 5 | 10 |
| Neutropenia | D009503 | — | D70 | — | — | 4 | — | 2 | 6 |
| Malaria | D008288 | EFO_0001068 | B54 | — | — | 1 | — | 4 | 5 |
| Liver diseases | D008107 | EFO_0001421 | K70-K77 | — | 4 | 1 | — | — | 5 |
| Intraabdominal infections | D059413 | — | — | — | — | 5 | — | — | 5 |
| Neoplasms | D009369 | — | C80 | 1 | 1 | 3 | — | 1 | 5 |
| Covid-19 | D000086382 | — | U07.1 | — | — | 2 | — | 2 | 4 |
| Kidney diseases | D007674 | EFO_0003086 | N08 | — | — | 1 | — | 3 | 4 |
| Periodontal pocket | D010514 | EFO_1001393 | — | — | — | 2 | — | 1 | 3 |
| Parkinson disease | D010300 | EFO_0002508 | G20 | — | — | 1 | — | 2 | 3 |
Show 66 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| B-cell lymphoma marginal zone | D018442 | — | C88.4 | — | 1 | — | — | 4 | 5 |
| Pulmonary tuberculosis | D014397 | EFO_1000049 | A15 | — | 5 | — | — | — | 5 |
| Non-alcoholic fatty liver disease | D065626 | EFO_0003095 | K75.81 | — | 4 | — | — | — | 4 |
| Fatty liver | D005234 | EFO_0003934 | — | — | 4 | — | — | — | 4 |
| Obesity | D009765 | EFO_0001073 | E66.9 | 1 | 1 | — | — | 3 | 4 |
| Insulin resistance | D007333 | EFO_0002614 | E88.819 | — | 1 | — | — | 1 | 2 |
| Colorectal neoplasms | D015179 | — | — | — | 1 | — | — | 1 | 2 |
| Empyema | D004653 | EFO_0003097 | — | — | 1 | — | — | 1 | 2 |
| B-cell lymphoma | D016393 | — | — | — | 1 | — | — | 1 | 2 |
| Tonsillectomy | D014068 | — | — | 1 | 1 | — | — | 1 | 2 |
Show 23 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Chemical and drug induced liver injury | D056486 | EFO_0004228 | — | 1 | — | — | — | 2 | 3 |
| Atrophy | D001284 | — | — | 1 | — | — | — | 2 | 3 |
| Pregnancy rate | D018873 | — | — | 1 | — | — | — | 1 | 2 |
| Drug interactions | D004347 | — | — | 2 | — | — | — | — | 2 |
| Respiration disorders | D012120 | — | J00-J99 | 2 | — | — | — | — | 2 |
| Bone regeneration | D001861 | — | — | 1 | — | — | — | 1 | 2 |
| Jaw fractures | D007572 | — | — | 1 | — | — | — | — | 1 |
| Gastrointestinal motility | D005769 | — | — | 1 | — | — | — | — | 1 |
| Brain neoplasms | D001932 | EFO_0003833 | C71 | 1 | — | — | — | — | 1 |
| Glioblastoma | D005909 | EFO_0000515 | — | 1 | — | — | — | — | 1 |
Show 6 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Kwashiorkor | D007732 | EFO_1001009 | E40 | — | — | — | — | 4 | 4 |
| Edentulous mouth | D009066 | — | — | — | — | — | — | 3 | 3 |
| Gastrointestinal microbiome | D000069196 | — | — | — | — | — | — | 3 | 3 |
| Hiv infections | D015658 | EFO_0000764 | B20 | — | — | — | — | 2 | 2 |
| Bisphosphonate-associated osteonecrosis of the jaw | D059266 | — | — | — | — | — | — | 2 | 2 |
| Arthritis | D001168 | EFO_0005856 | M05-M14 | — | — | — | — | 2 | 2 |
| Renal insufficiency | D051437 | — | N19 | — | — | — | — | 2 | 2 |
| Renal dialysis | D006435 | EFO_0010690 | Z99.2 | — | — | — | — | 2 | 2 |
| Enterococcus | D016983 | — | — | — | — | — | — | 2 | 2 |
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | — | — | — | 2 | 2 |
Show 116 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Amoxicillin |
| INN | amoxicillin |
| Description | Amoxicillin is a penicillin in which the substituent at position 6 of the penam ring is a 2-amino-2-(4-hydroxyphenyl)acetamido group. It has a role as an antibacterial drug. It is a penicillin and a penicillin allergen. It is a conjugate acid of an amoxicillin(1-). |
| Classification | Small molecule |
| Drug class | penicillins |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(=O)O |
Identifiers
| PDB | — |
| CAS-ID | 26787-78-0 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1082 |
| ChEBI ID | 2676 |
| PubChem CID | 33613 |
| DrugBank | DB01060 |
| UNII ID | 9EM05410Q9 (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Amoxicillin
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Amoxicillin
+
Lansoprazole
+
Clarithromycin
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Amoxicillin
+
Omeprazole
+
Clarithromycin
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Amoxicillin
+
Clavulanic acid
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 80,879 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
70,522 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use